NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · page 21 of 33
The chart highlights a 17.2% attenuation in the decline of SVC scores for the PrimeC group compared to placebo.
Pitch deck · traction · show_traction · balanced density
Slide locked Sign in to view
Slide schematic 5/5
chart 1/1 disclaimer 1/1 source-note 1/1 title 2/2
Components 5
line disclaimer source-note action-title headline
Tools 1
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 0
∅
No frameworks
No framework match is anchored to this slide.